Phencyclidine

3-meo-pcp is an exploration substance recorded as a dissociative synthetic and also a simple of Phencyclidine. The IUPAC name for this synthetic is 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine and the CAS number is 91164-58-8. There is restricted logical data on 3-meo-pcp however the information accessible incorporate the atomic equation which is C18H27NO weight 273.41, and that this compound transports serotonin with more noteworthy liking than PCP while official to the NMDA receptor.

Read More »

3-meo-pcp

3-meo-pcp is a research chemical listed as a dissociative chemical as well as an analog of Phencyclidine. The IUPAC name for this chemical is 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine and the CAS number is 91164-58-8. There is limited scientific information on 3-meo-pcp but the data available include the molecular formula which is C18H27NO weight 273.41, and that this chemical transports serotonin with greater affinity than PCP while binding to the NMDA receptor.

When laboratories purchase 3-meo-pcp for research purposes it will come as a powder. Some of the data compiled by the United States Environmental Protection Agency and ACD/Labs includes scientific data that will aid scientists in their research. Some of the data include the flash point, boiling point, index of refraction, surface tension, vapor pressure estimates, and water solubility. More studies need to be performed in a controlled laboratory to discover any benefits the chemical may have for humans whether medically or mentally while ensuring fewer side effects.

Read More »

ab-fubinaca Strong Agonist

ab-fubinaca Strong Agonist
Compounds for research such as ab-fubinaca are known to bind to the cannabinoid receptors which will active these receptors and create a biological action. The receptors are called CB1 and CB2. Cannabinoid receptors are found throughout the animal and human body and are known to be part of the endocannabinoid system. These receptors involve different physiological processes which include memory, mood, pain, and appetite.
ab-fubinaca was first developed using synthetic substances in 2009 by Pfizer to be used as an analgesic medicine, however, it has never been used on humans. Today, ab-fubinaca can be purchased from a compound supplier to discover more properties of the research chemicals and determine if the chemical will benefit humans in any fashion. Psychoactive compounds like ab-fubinaca do have a few legal issues in some countries such as in the United States it was listed as a Schedule I chemical in 2014 making it a controlled substance. The same goes for Germany and China.

Read More »